Clinical characteristics and treatment outcome of childhood acute lymphoblastic leukemia in Saudi Arabia: A multi-institutional retrospective national collaborative study

Pediatric Blood and Cancer

Volumn 61, Issue 1, 2014, Pages 74-80

  Al Sudairy, Reem ^a   Al Nasser, Abdullah ^b,c   Alsultan, Abdulrahman ^d   Ahmari, Ali Al ^b   Abosoudah, Ibraheem ^b   Al Hayek, Reema ^e   Al Harbi, Talal ^a   Al Manjomi, Fahad ^f   Al Harbi, Musa ^f   Al Ghamdi, Hasna ^g   Al Shahrani, Mohammed ^h   Belgaumi, Asim F ^b,i  

^a KING FAHAD NATIONAL GUARD HOSPITAL   (Saudi Arabia)

^b KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^c Department of Pediatrics Hamad Medical City ^*  (Qatar)

^d KING KHALID UNIVERSITY HOSPITAL   (Saudi Arabia)

^e KING FAHAD SPECIALIST HOSPITAL   (Saudi Arabia)

^f KING FAHAD MEDICAL CITY   (Saudi Arabia)

^g King Abdulaziz Medical City   (Saudi Arabia)

^h Prince Sultan Military Medical City   (Saudi Arabia)

ⁱ ALFAISAL UNIVERSITY   (Saudi Arabia)

Author keywords

Acute lymphoblastic leukemia; Childhood; Outcome

Indexed keywords

ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; DNA; MIXED LINEAGE LEUKEMIA PROTEIN; TRANSCRIPTION FACTOR ETV6; TRANSCRIPTION FACTOR RUNX1;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RISK; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM LEUKEMIA; CHILD; CHILDHOOD LEUKEMIA; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENE REARRANGEMENT; GENE TRANSLOCATION; GENETIC PREDISPOSITION; GENETIC RISK; HUMAN; INDUCTION CHEMOTHERAPY; INFANT; KARYOTYPING; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; PLOIDY; PRE B LYMPHOCYTE; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; SAUDI ARABIA; TRISOMY; CANCER PATIENT; MULTICENTER STUDY; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; SEX DIFFERENCE; CLINICAL TRIAL; DISEASE FREE SURVIVAL; FACTUAL DATABASE; GENETICS; PATHOLOGY; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRESCHOOL CHILD; TREATMENT OUTCOME;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; DATABASES, FACTUAL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INFANT; MALE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RETROSPECTIVE STUDIES; SAUDI ARABIA; TREATMENT OUTCOME;

EID: 84891699834     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24584     Document Type: Article

References (43)

1. Smith M, Gloeckler-Ries LA. Childhood cancer: Incidence, survival and mortality. In: Pizzo P, Poplack DG, editors. Principles and practice of pediatric oncology, 4th edition. Lippincott: Williams & Wilkins; 2002; 1-12.
2. Mostert S, Njuguna F, Kemps L, et al. Epidemiology of diagnosed childhood cancer in Western Kenya. Arch Dis Child 2012;97:508-512.
3. Arora RS, Eden TO, Kapoor G. Epidemiology of childhood cancer in India. Indian J Cancer 2009;46:264-273.
4. Kaatsch P. Epidemiology of childhood cancer. Cancer Treat Rev 2010;36:277-285.
5. Valsecchi MG, Tognoni G, Bonilla M, et al. Clinical epidemiology of childhood cancer in Central America and Caribbean countries. Ann Oncol 2004;15:680-685.
6. Jeha S, Pui CH. Risk-adapted treatment of pediatric acute lymphoblastic leukemia. Hematol Oncol Clin North Am 2009;23:973-990.
7. Stanulla M, Schrappe M. Treatment of childhood acute lymphoblastic leukemia. Semin Hematol 2009;46:52-63.
8. Gaynon PS, Angiolillo AL, Carroll WL, et al. Long-term results of the children's cancer group studies for childhood acute lymphoblastic leukemia 1983-2002: A Children's Oncology Group Report. Leukemia 2010;24:285-297.
9. Hunger SP, Lu X, Devidas M, et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: A report from the children's oncology group. J Clin Oncol 2012;30:1663-1669.
10. Antillon F, de Maselli T, Garcia T, et al. Nutritional status of children during treatment for acute lymphoblastic leukemia in the Central American Pediatric Hematology Oncology Association (AHOPCA): Preliminary data from Guatemala. Pediatr Blood Cancer 2008;50:502-505; discussion 517.
11. Hazar V, Karasu GT, Uygun V, et al. Childhood acute lymphoblastic leukemia in Turkey: Factors influencing treatment and outcome: A single center experience. J Pediatr Hematol Oncol 2010;32:e317- e322.
12. Kulkarni KP, Arora RS, Marwaha RK. Survival outcome of childhood acute lymphoblastic leukemia in India: A resource-limited perspective of more than 40 years. J Pediatr Hematol Oncol 2011;33:475-479.
13. Luo XQ, Ke ZY, Huang LB, et al. High-risk childhood acute lymphoblastic leukemia in China: Factors influencing the treatment and outcome. Pediatr Blood Cancer 2009;52:191-195.
14. Metzger ML, Howard SC, Fu LC, et al. Outcome of childhood acute lymphoblastic leukaemia in resource-poor countries. Lancet 2003;362:706-708.
15. Sitaresmi MN, Mostert S, Schook RM, et al. Treatment refusal and abandonment in childhood acute lymphoblastic leukemia in Indonesia: An analysis of causes and consequences. Psychooncology 2010;19:361-367.
16. Al-Nasser A, El-Solh H, De Vol E, et al. Improved outcome for children with acute lymphoblastic leukemia after risk-adjusted intensive therapy: A single-institution experience. Ann Saudi Med 2008;28:251-259.
17. Smith M, Arthur D, Camitta B, et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol 1996;14:18-24.
18. Lange BJ, Bostrom BC, Cherlow JM, et al. Double-delayed intensification improves event-free survival for children with intermediate-risk acute lymphoblastic leukemia: A report from the Children's Cancer Group. Blood 2002;99:825-833.
19. Nachman J, Sather HN, Cherlow JM, et al. Response of children with high-risk acute lymphoblastic leukemia treated with and without cranial irradiation: A report from the Children's Cancer Group. J Clin Oncol 1998;16:920-930.
20. Seibel NL, Steinherz PG, Sather HN, et al. Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: A report from the Children's Oncology Group. Blood 2008;111:2548-2555.
21. Matloub Y, Bostrom BC, Hunger SP, et al. Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: A report from the Children's Oncology Group. Blood 2011;118:243-251.
22. Pui CH, Sandlund JT, Pei D, et al. Improved outcome for children with acute lymphoblastic leukemia: Results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. Blood 2004;104:2690- 2696.
23. Schrappe M, Reiter A, Ludwig WD, et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: Results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group. Blood 2000;95:3310-3322.
24. Hann I, Vora A, Harrison G, et al. Determinants of outcome after intensified therapy of childhood lymphoblastic leukaemia: Results from Medical Research Council United Kingdom acute lymphoblastic leukaemia XI protocol. Br J Haematol 2001;113:103-114.
25. Saudi Cancer Registry MoH, Kingdom of Saudi Arabia. Cancer Incidence and Survival Report; Saudi Arabia 2007. In Bazarbashi S, Al-Zahrani, A (ed) Edition 2007.
26. Rajalekshmy KR, Abitha AR, Anuratha N, et al. Time trend in frequency of occurrence of major immunophenotypes in paediatric acute lymphoblastic leukemia cases as experienced by Cancer Institute, Chennai, south India during the period 1989-2009. Indian J Cancer 2011;48:310-315.
27. Greaves MF, Colman SM, Beard ME, et al. Geographical distribution of acute lymphoblastic leukaemia subtypes: Second report of the collaborative group study. Leukemia 1993;7:27-34.
28. Ramot B, Magrath I. Hypothesis: The environment is a major determinant of the immunological sub-type of lymphoma and acute lymphoblastic leukaemia in children. Br J Haematol 1982;50:183-189.
29. Pui CH, Carroll WL, Meshinchi S, et al. Biology, risk stratification, and therapy of pediatric acute leukemias: An update. J Clin Oncol 2011;29:551-565.
30. Bonilla M, Moreno N, Marina N, et al. Acute lymphoblastic leukemia in a developing country: Preliminary results of a nonrandomized clinical trial in El Salvador. J Pediatr Hematol Oncol 2000;22:495-501.
31. Halalsheh H, Abuirmeileh N, Rihani R, et al. Outcome of childhood acute lymphoblastic leukemia in Jordan. Pediatr Blood Cancer 2011;57:385-391.
32. Hill A, Short MA, Varghese C, et al. The t(12:21) is underrepresented in childhood B-lineage acute lymphoblastic leukemia in Kerala, Southern India. Haematologica 2005;90:414-416.
33. Siddiqui R, Nancy N, Naing WP, et al. Distribution of common genetic subgroups in childhood acute lymphoblastic leukemia in four developing countries. Cancer Genet Cytogenet 2010;200:149- 153.
34. Siraj AK, Kamat S, Gutierrez MI, et al. Frequencies of the major subgroups of precursor B-cell acute lymphoblastic leukemia in Indian children differ from the West. Leukemia 2003;17:1192-1193.
35. Borkhardt A, Cazzaniga G, Viehmann S, et al. Incidence and clinical relevance of TEL/AML1 fusion genes in children with acute lymphoblastic leukemia enrolled in the German and Italian multicenter therapy trials. Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Munster Study Group. Blood 1997;90:571-577.
36. Shurtleff SA, Buijs A, Behm FG, et al. TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis. Leukemia 1995;9:1985-1989.
37. Sirvent N, Suciu S, Rialland X, et al. Prognostic significance of the initial cerebro-spinal fluid (CSF) involvement of children with acute lymphoblastic leukaemia (ALL) treated without cranial irradiation: Results of European Organization for Research and Treatment of Cancer (EORTC) Children Leukemia Group study 58881. Eur J Cancer 2011;47:239-247.
38. Gao C, Zhao XX, Li WJ, et al. Clinical features, early treatment responses, and outcomes of pediatric acute lymphoblastic leukemia in China with or without specific fusion transcripts: A single institutional study of 1,004 patients. Am J Hematol 2012;87:1022-1027.
39. Ensor HM, Schwab C, Russell LJ, et al. Demographic, clinical, and outcome features of children with acute lymphoblastic leukemia and CRLF2 deregulation: Results from the MRC ALL97 clinical trial. Blood 2011;117:2129-2136.
40. Hijiya N, LiuW, Sandlund JT, et al. Overt testicular disease at diagnosis of childhood acute lymphoblastic leukemia: Lack of therapeutic role of local irradiation. Leukemia 2005;19:1399-1403.
41. Marwaha RK, Kulkarni KP, Bansal D, et al. Overt testicular disease at diagnosis in childhood acute lymphoblastic leukemia: Prognostic significance and role of testicular irradiation. Indian J Pediatr 2010;77:779-783.
42. Sirvent N, Suciu S, Bertrand Y, et al. Overt testicular disease (OTD) at diagnosis is not associated with a poor prognosis in childhood acute lymphoblastic leukemia: Results of the EORTC CLG Study 58881. Pediatr Blood Cancer 2007;49:344-348.
43. Nachman JB, Sather HN, Sensel MG, et al. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med 1998;338:1663-1671.